Yun HJ - Search Results

1

Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.

Kim Y, Yun HJ, Choi KH, Kim CW, Lee JH, Weicker R, Kim SM, Park KC. Kim Y, et al. Among authors: yun hj. Int J Mol Sci. 2023 Nov 16;24(22):16413. doi: 10.3390/ijms242216413. Int J Mol Sci. 2023. PMID: 38003602 Free PMC article.

2

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models.

Yun HJ, Kim HJ, Kim J, Kim SY, Chang HS, Park CS, Chang HJ, Park KC. Yun HJ, et al. Int J Mol Sci. 2021 Jan 7;22(2):536. doi: 10.3390/ijms22020536. Int J Mol Sci. 2021. PMID: 33430361 Free PMC article.

3

Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer.

Yun HJ, Kim M, Kim SY, Fang S, Kim Y, Chang HS, Chang HJ, Park KC. Yun HJ, et al. Int J Mol Sci. 2022 Jan 9;23(2):699. doi: 10.3390/ijms23020699. Int J Mol Sci. 2022. PMID: 35054884 Free PMC article.

4

Aggressiveness of Differentiated Thyroid Carcinoma in Pediatric Patients Younger Than 16 years: A Propensity Score-Matched Analysis.

Kim SY, Yun HJ, Chang H, Kim SM, Jeon S, Lee S, Lee YS, Chang HS, Park CS. Kim SY, et al. Among authors: yun hj. Front Oncol. 2022 Apr 26;12:872130. doi: 10.3389/fonc.2022.872130. eCollection 2022. Front Oncol. 2022. PMID: 35558513 Free PMC article.

5

Prophylactic antibiotics may not be necessary for transoral endoscopic thyroidectomy.

Lee JS, Kim HJ, Lee JS, Yun HJ, Lee S, Cheong JH, Kim SY, Kim SM, Chang H, Lee YS, Park CS, Chang HS. Lee JS, et al. Among authors: yun hj. Front Surg. 2022 Aug 2;9:940391. doi: 10.3389/fsurg.2022.940391. eCollection 2022. Front Surg. 2022. PMID: 35983550 Free PMC article.

6

Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model.

Yun HJ, Lim JH, Kim SY, Kim SM, Park KC. Yun HJ, et al. Biomedicines. 2022 Aug 5;10(8):1901. doi: 10.3390/biomedicines10081901. Biomedicines. 2022. PMID: 36009450 Free PMC article.

7

Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.

Kim SM, Park K, Lim JH, Yun HJ, Kim SY, Choi KH, Kim CW, Lee JH, Weicker R, Pan CH, Park KC. Kim SM, et al. Among authors: yun hj. Int J Mol Sci. 2022 Sep 8;23(18):10378. doi: 10.3390/ijms231810378. Int J Mol Sci. 2022. PMID: 36142303 Free PMC article.

8

Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.

Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS. Lee JS, et al. Among authors: yun hj. J Clin Endocrinol Metab. 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. J Clin Endocrinol Metab. 2023. PMID: 36546348 Free PMC article. Review.

9

Anti-Cancer SERCA Inhibitors Targeting Sorafenib-Resistant Human Papillary Thyroid Carcinoma.

Chang HS, Kim Y, Lee SY, Yun HJ, Chang HJ, Park KC. Chang HS, et al. Among authors: yun hj. Int J Mol Sci. 2023 Apr 11;24(8):7069. doi: 10.3390/ijms24087069. Int J Mol Sci. 2023. PMID: 37108231 Free PMC article.

10

Clinicopathological and Genetic Characteristics of Patients of Different Ages with Diffuse Sclerosing Variant Papillary Thyroid Carcinoma.

Kim SY, Shin SJ, Lee DG, Yun HJ, Kim SM, Chang H, Chang HS, Shin H, Lee YS. Kim SY, et al. Among authors: yun hj. Cancers (Basel). 2023 Jun 7;15(12):3101. doi: 10.3390/cancers15123101. Cancers (Basel). 2023. PMID: 37370711 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

449 results

Search Page

Filters